You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Guideline-Directed Therapy for Heart Failure: Challenges and Solutions

  • Authors: Ileana L. Piña, MD, MPH; Javed Butler, MD, MBA, MPH; Katherine Di Palo, PharmD, BCACP, BCGP
  • CME / ABIM MOC / CE Released: 8/26/2020
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 8/26/2021, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for nephrologists, cardiologists, primary care physicians, nurses/nurse practitioners, and pharmacists

The goal of this activity is to discuss treatment strategies for patients with heart failure (HF) and how to balance the risk for hyperkalemia from the use of effective doses of renin-angiotensin-aldosterone system inhibitors (RAASis) and mineralocorticoid receptor antagonists in these patients.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Guideline-based recommendations for clinical management of HF
    • Special considerations related to RAASi use in patients with HF
  • Have greater competence related to
    • Solutions that team members can implement to overcome common challenges pertaining to RAAS enablement in patients with HF


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Ileana L. Piña, MD, MPH

    Professor of Medicine
    Wayne State University
    Clinical Professor of Medicine
    Central Michigan University
    Director CVD, Research and Academic Affairs
    Regional and National Director of Heart Failure
    Detroit Medical Center
    Detroit, Michigan

    Disclosures

    Disclosure: Ileana L. Piña, MD, MPH, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Vifor Pharma

Panelists

  • Javed Butler, MD, MBA, MPH

    Patrick A. Lehan Chair in Cardiovascular Research
    Professor of Medicine and Physiology
    University of Mississippi
    Jackson, Mississippi

    Disclosures

    Disclosure: Javed Butler, MD, MBA, MPH, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Abbott Laboratories; Amgen Inc.; Array; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVRx, Inc.; G3 Pharmaceutical; Innolife; Janssen Pharmaceuticals, Inc.; LinaNova; Luitpold Pharmaceuticals; Medtronic, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Relypsa, Inc.
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc./Lilly; Janssen Pharmaceuticals, Inc; Novartis Pharmaceuticals Corporation

  • Katherine Di Palo, PharmD, BCACP, BCGP

    Clinical Program Manager
    Hospital Readmissions Reduction Program
    Montefiore Medical Center
    New York, New York

    Disclosures

    Disclosure: Katherine Di Palo, PharmD, BCACP, BCGP, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: Vifor Pharma

Editor

  • George Boutsalis, PhD

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: George Boutsalis, PhD, has disclosed no relevant financial relationships.

CME Reviewer

  • Hazel Dennison, DNP, RN, FNP, CHCP,CPHQ, CNE

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Hazel Dennison, DNP, RN, FNP, CHCP,CPHQ, CNE, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number JA0007105-0000-20-355-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Guideline-Directed Therapy for Heart Failure: Challenges and Solutions

Authors: Ileana L. Piña, MD, MPH; Javed Butler, MD, MBA, MPH; Katherine Di Palo, PharmD, BCACP, BCGPFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 8/26/2020

Valid for credit through: 8/26/2021, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is to discuss treatment strategies for patients with heart failure (HF) and how to balance the risk of hyperkalemia from the use of effective doses of [renin-angiotensin-aldosterone system (RAAS)] inhibitors and [mineralocorticoid receptor antagonists (MRAs)] in these patients

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print